Effect of Probiotic on Rhinovirus Induced Colds (MK EPRIC)
Primary Purpose
Common Cold
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bifidobacterium animalis subsp. lactis Bl-04
sucrose
Sponsored by
About this trial
This is an interventional prevention trial for Common Cold
Eligibility Criteria
Inclusion Criteria:
INCLUSION CRITERIA AT ENROLLMENT:
- Subject must be 18-60 years of age.
- Subject must read and sign a copy of the approved Consent Form
- Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39
INCLUSION CRITERIA AT DAY -28
• Female subjects must be using an effective birth control method.
INCLUSION CRITERIA AT CHALLENGE:
- Female subjects must be using an effective birth control method.
Exclusion Criteria:
Antibiotic use within 3 months prior to day -28
- Female subjects with a positive urine pregnancy screen
- History of use of probiotics in the preceding two weeks
- Current cancer diagnosis or immunosuppressive therapy in the last 6 months
- Any clinically significant abnormalities of the upper respiratory tract
- Any clinically significant acute or chronic respiratory illness
- Any clinically significant bleeding tendency by history
- Hypertension that requires treatment with antihypertensive medications
- History of angina or other clinically significant cardiac disease
- Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
- History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks
- History of drug or alcohol abuse in the 6 months preceding the study
EXCLUSION CRITERIA AT CHALLENGE:
- Any upper respiratory infection or allergic rhinitis in the two weeks prior to the challenge
- Female subjects with positive pregnancy screen prior to challenge
- Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
- Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation in the two weeks prior to the challenge
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Bifidobacterium lactis Bl-04
Placebo
Arm Description
2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
sucrose
Outcomes
Primary Outcome Measures
Number of Participants With Rhinovirus-associated Illness Episodes
Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.
Secondary Outcome Measures
Full Information
NCT ID
NCT02679807
First Posted
February 8, 2016
Last Updated
March 16, 2020
Sponsor
University of Virginia
Collaborators
Danisco Sweeteners Oy
1. Study Identification
Unique Protocol Identification Number
NCT02679807
Brief Title
Effect of Probiotic on Rhinovirus Induced Colds
Acronym
MK EPRIC
Official Title
Effect of Probiotic on Rhinovirus Induced Colds
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
April 2018 (Actual)
Study Completion Date
April 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia
Collaborators
Danisco Sweeteners Oy
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized, double-blind placebo controlled trial to evaluate the effect of a probiotic (Bl-04) on the occurrence of rhinovirus-associated common cold illness in the experimental rhinovirus challenge model. A previous study documented that Bl-04 has significant effects on the innate immune response in the nose and this study will be powered to assess whether these effects translate into a demonstrable clinical benefit. Volunteers will be given Bl-04 or placebo for 28 days then challenged with rhinovirus. The primary analysis will be on the proportion of volunteers who develop a rhinovirus associated illness in the two treatment groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Common Cold
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
380 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bifidobacterium lactis Bl-04
Arm Type
Active Comparator
Arm Description
2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
sucrose
Intervention Type
Biological
Intervention Name(s)
Bifidobacterium animalis subsp. lactis Bl-04
Intervention Type
Other
Intervention Name(s)
sucrose
Primary Outcome Measure Information:
Title
Number of Participants With Rhinovirus-associated Illness Episodes
Description
Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.
Time Frame
5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
INCLUSION CRITERIA AT ENROLLMENT:
Subject must be 18-60 years of age.
Subject must read and sign a copy of the approved Consent Form
Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39
INCLUSION CRITERIA AT DAY -28
• Female subjects must be using an effective birth control method.
INCLUSION CRITERIA AT CHALLENGE:
Female subjects must be using an effective birth control method.
Exclusion Criteria:
Antibiotic use within 3 months prior to day -28
Female subjects with a positive urine pregnancy screen
History of use of probiotics in the preceding two weeks
Current cancer diagnosis or immunosuppressive therapy in the last 6 months
Any clinically significant abnormalities of the upper respiratory tract
Any clinically significant acute or chronic respiratory illness
Any clinically significant bleeding tendency by history
Hypertension that requires treatment with antihypertensive medications
History of angina or other clinically significant cardiac disease
Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks
History of drug or alcohol abuse in the 6 months preceding the study
EXCLUSION CRITERIA AT CHALLENGE:
Any upper respiratory infection or allergic rhinitis in the two weeks prior to the challenge
Female subjects with positive pregnancy screen prior to challenge
Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation in the two weeks prior to the challenge
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34927036
Citation
Turner RB, Lehtoranta L, Hibberd A, Mannikko S, Zabel B, Yeung N, Huttunen T, Burns FR, Lehtinen MJ. Effect of Bifidobacterium animalis spp. lactis Bl-04 on Rhinovirus-Induced Colds: A Randomized, Placebo-Controlled, Single-Center, Phase II Trial in Healthy Volunteers. EClinicalMedicine. 2021 Dec 3;43:101224. doi: 10.1016/j.eclinm.2021.101224. eCollection 2022 Jan.
Results Reference
derived
Learn more about this trial
Effect of Probiotic on Rhinovirus Induced Colds
We'll reach out to this number within 24 hrs